Skip to main content
. 2024 Jun 29;27(8):110425. doi: 10.1016/j.isci.2024.110425

Figure 3.

Figure 3

Recurrence-free survival stratified by treatment, shown for patients with low and high number of stromal tumor-infiltrating lymphocytes (sTILs)

(A–D) Kaplan-Meier curve for clinical high-risk patients. Triple-negative breast cancer and sTILs abundance labeled as low (<20%; A) and high (≥20%; B). Test for interaction (p 0.02) is calculated in Table 3. Patients with hormone receptor (HR)-positive human epidermal growth factor receptor 2 (HER2)-negative (HR+HER2−)tumors, low sTILs <10%: C), and high sTILs (≥10%; D). Test for interaction (p 0.16) is calculated in Table 4. Unadjusted cox proportional hazard ratio with a 95% confidence interval (CI) and corresponding p value is shown. A, doxorubicin; C, cyclophosphamide; T, docetaxel; dd, dose-dense.